| 摘要 |
PROBLEM TO BE SOLVED: To provide improved reagents and methods for modulating B cell functions in B cell disorders such as B cell malignant tumor and autoimmune diseases.SOLUTION: The above problem was solved by providing a monoclonal antibody (mAb) and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides a method for using monoclonal antibodies, antigen binding fragments and pharmaceutical compositions, for example, in methods of depleting B cells or treating B cell disorders. The invention also provides cells, nucleic acids, and methods for producing the monoclonal antibodies. In one embodiment, the binding density of the mAb or antigen-binding fragment thereof to B cells is at least two-fold higher than the density of binding of one or more conventional mAbs (e.g., mAb 1F5) to B cells and/or malignant counterparts thereof.SELECTED DRAWING: None |
